

**Literaturverzeichnis zum Variabeitrag „Kopfschmerzen nach der Impfung mit dem COVID-19-Impfstoff von AstraZeneca“
von Privatdozentin Dr. Stefanie Förderreuther
Bayerisches Ärzteblatt 5/2021, Seite 210 f.**

1. Kristoffersen ES, Harper CE, Vetvik KG, Zarnovicky S, Hansen JM, Faiz KW. Incidence and Mortality of Cerebral Venous Thrombosis in a Norwegian Population. *Stroke*. 2020;51(10):3023-9.
2. Agrawal K, Burger K, Rothrock JF. Cerebral Sinus Thrombosis. *Headache*. 2016;56(8):1380-9.
3. Coutinho JM, Zuurbier SM, Aramideh M, Stam J. The incidence of cerebral venous thrombosis: a cross-sectional study. *Stroke*. 2012;43(12):3375-7.
4. Zuurbier SM, Hiltunen S, Lindgren E, Silvis SM, Jood K, Devasagayam S, et al. Cerebral Venous Thrombosis in Older Patients. *Stroke*. 2018;49(1):197-200.
5. de Bruijn SF, Stam J, Kappelle LJ. Thunderclap headache as first symptom of cerebral venous sinus thrombosis. CVST Study Group. *Lancet (London, England)*. 1996;348(9042):1623-5.
6. Capecchi M, Abbattista M, Martinelli I. Cerebral venous sinus thrombosis. *Journal of thrombosis and haemostasis : JTH*. 2018;16(10):1918-31.
7. Coutinho JM, Stam J, Canhão P, Barinagarrementeria F, Bousser MG, Ferro JM. Cerebral venous thrombosis in the absence of headache. *Stroke*. 2015;46(1):245-7.
8. Alet M, Ciardi C, Alemán A, Bando L, Bonardo P, Cea C, et al. Cerebral venous thrombosis in Argentina: clinical presentation, predisposing factors, outcomes and literature review. *Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association*. 2020;29(10):105145.
9. Ferro JM, Correia M, Pontes C, Baptista MV, Pita F. Cerebral vein and dural sinus thrombosis in Portugal: 1980-1998. *Cerebrovascular diseases (Basel, Switzerland)*. 2001;11(3):177-82.
10. Masuhr F, Busch M, Amberger N, Ortwein H, Weih M, Neumann K, et al. Risk and predictors of early epileptic seizures in acute cerebral venous and sinus thrombosis. *European journal of neurology*. 2006;13(8):852-6.
11. Mehvari Habibabadi J, Saadatnia M, Tabrizi N. Seizure in cerebral venous and sinus thrombosis. *Epilepsia open*. 2018;3(3):316-22.
12. Lan R, Ma YZ, Shen XM, Wu JT, Gu CQ, Zhang Y. Bilateral corpus callosum and corona radiata infarction due to cerebral venous sinus thrombosis presenting as headache and acute reversible aphasia: a rare case report. *BMC neurology*. 2020;20(1):249.
13. van den Bergh WM, van der Schaaf I, van Gijn J. The spectrum of presentations of venous infarction caused by deep cerebral vein thrombosis. *Neurology*. 2005;65(2):192-6.
14. Miranda B, Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F, et al. Venous thromboembolic events after cerebral vein thrombosis. *Stroke*. 2010;41(9):1901-6.
15. Oldenburg J, Klamroth R, Langer F, Albisetti M, von Auer C, Ay C, et al. Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH. *Hamostaseologie*. 2021.
16. Weimar C, Holzhauer S, Knoflach M, Koennecke HC, Masuhr F, Mono ML, et al. [Cerebral venous and sinus thrombosis : S2k guidelines]. *Der Nervenarzt*. 2019;90(4):379-87.

17. Buyck PJ, Zuurbier SM, Garcia-Esperon C, Barboza MA, Costa P, Escudero I, et al. Diagnostic accuracy of noncontrast CT imaging markers in cerebral venous thrombosis. *Neurology*. 2019;92(8):e841-e51.
18. Crassard I, Soria C, Tzourio C, Woimant F, Drouet L, Ducros A, et al. A negative D-dimer assay does not rule out cerebral venous thrombosis: a series of seventy-three patients. *Stroke*. 2005;36(8):1716-9.
19. Dentali F, Squizzato A, Marchesi C, Bonzini M, Ferro JM, Ageno W. D-dimer testing in the diagnosis of cerebral vein thrombosis: a systematic review and a meta-analysis of the literature. *Journal of thrombosis and haemostasis : JTH*. 2012;10(4):582-9.
20. Tubis S, Hinterding K. COVID-19 Vaccine AstraZeneca: Risiko von Thrombozytopenie und Gerinnungsstörungen 2021 [Available from: <https://www.akdae.de/Arzneimittelsicherheit/RHB/20210324.pdf>].
21. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet (London, England)*. 2020;396(10249):467-78.
22. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. *Lancet (London, England)*. 2021;396(10267):1979-93.
23. Silvis SM, Hiltunen S, Lindgren E, Jood K, Zuurbier SM, Middeldorp S, et al. Cancer and risk of cerebral venous thrombosis: a case-control study. *Journal of thrombosis and haemostasis : JTH*. 2018;16(1):90-5.
24. Silvis SM, Middeldorp S, Zuurbier SM, Cannegieter SC, Coutinho JM. Risk Factors for Cerebral Venous Thrombosis. *Seminars in thrombosis and hemostasis*. 2016;42(6):622-31.